Document is current
Any future updates will be listed below
-
Authors
Ostrem, Jonathan M. L. http://orcid.org/0000-0001-9085-1615
Peters, Ulf
Shokat, Kevan M. http://orcid.org/0000-0001-8590-7741
- License Information
-
More Information
Article History
First Online: 26 July 2024
Competing interests
: K.M.S. has received stock and monetary compensation from KRAS<sup>G12C</sup> patents licensed to Araxes Pharma, and currently receives stock and/or monetary compensation from: Apertor, BioTheryX, BridGene Biosciences, Denali Therapeutics, eFFECTOR Therapeutics, Erasca, G Protein Therapeutics, Genentech/Roche, Ikena, Initial Therapeutics, Lyterian, Kumquat Biosciences, Kura Oncology, Merck, Mitokinin, Montara, Nested, Nextech, Radd Pharma, Revolution Medicines, Rezo, Totus, Turning Point, Type6 Therapeutics, Wellspring Biosciences (Araxes Pharma), Vevo and Vicinitas. U.P. has received stock and monetary compensation from KRASG12C patents licensed to Araxes Pharma, and currently receives stock and/or monetary compensation from Araxes Pharma and Kumquat Biosciences. J.M.L.O. has received stock and monetary compensation from KRAS<sup>G12C</sup> patents licensed to Araxes Pharma.
